Active Recombinant Human CD22 Protein, His-tagged, FITC conjugated

• Cat.No.: CD22-3947HF
• Product Overview: FITC conjugated recombinant human CD22 protein (176-687aa) was expressed in HEK293 cells with His tag at C terminal.

Specification

• Description: B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2/CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2/CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
• Source: HEK293
• Species: Human
• Tag: His
• Form: Lyophilized
• Bio-activity: Immobilized Human CD22 Protein, His-tagged at 2 μg/mL (100 μL/well) can bind Anti-Human CD22 MAb, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
• Molecular Mass: The protein has a calculated MW of 57.8 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Endotoxin: < 1.0 EU/ μg by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE
• Characteristic: Disulfide-linked homodimer
  Labeled with FITC via amines
  Excitation source: 488 nm spectral line, argon-ion laser
  Excitation Wavelength: 488 nm
  Emission Wavelength: 535 nm
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
• Storage Buffer: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.

Gene Information

• Gene Name: CD22 CD22 molecule [ Homo sapiens ]
• Official Symbol: CD22
• Synonyms: CD22; CD22 molecule; CD22 antigen; B-cell receptor CD22; sialic acid binding Ig like lectin 2; SIGLEC 2; SIGLEC2; BL-CAM; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2; SIGLEC-2; FLJ22814; MGC130020
• Gene ID: 933
• mRNA Refseq: NM_001185099
• Protein Refseq: NP_001172028
• MIM: 107266
• UniProt ID: P20273

Reviews

01/15/2021

The CD22 protein offers numerous advantages in trials and research studies, making it an excellent choice for scientists in need of reliable and high-quality experimental materials.

06/15/2017

Its unique properties make CD22 an invaluable tool for investigating cellular signaling pathways, protein-protein interactions, and membrane dynamics.

02/17/2016

With the CD22 protein and its accompanying technical assistance, I am confident that I can achieve successful outcomes for my research endeavors.

Q&As

How does CD22-targeted immunotherapy differ from traditional chemotherapy?

CD22-targeted immunotherapy is more targeted, specifically attacking cancer cells, whereas chemotherapy affects both healthy and cancerous cells.

Can CD22-targeted therapies be used in combination with other cancer treatments?

Yes, CD22-targeted therapies are often used in combination with chemotherapy or other immunotherapies for enhanced efficacy.

What other diseases involve CD22 as a therapeutic target?

CD22-targeted therapies are being explored for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.

Are there any clinical applications of CD22 protein in cancer therapy?

Yes, CD22 is targeted in immunotherapy for B cell malignancies like acute lymphoblastic leukemia (ALL).

What role does CD22 play in B cell function?

CD22 acts as an inhibitory receptor, regulating B cell activation and signaling.